• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Etsy Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

    2/22/24 1:37:58 PM ET
    $ACVA
    $AGRX
    $AMLX
    $ATNI
    Real Estate
    Real Estate
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACVA alert in real time by email

    Shares of Etsy, Inc. (NASDAQ:ETSY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter financial results.

    Etsy reported quarterly earnings of 62 cents per share which missed the analyst consensus estimate of 78 cents. The company reported quarterly sales of $842.3 million, beating the analyst consensus estimate of $827.81 million.
    Etsy shares dipped 7.5% to $71.34 on Thursday.

    Here are some other stocks moving in today's mid-day session.

    Gainers

    • La Rosa Holdings Corp. (NASDAQ:LRHC) shares jumped 160.7% to $3.6499 after the company said it has acquired a 100% interest in the Company's franchisee - La Rosa Realty Winter Garden LLC located in Winter Garden, Florida.
    • BuzzFeed, Inc. (NASDAQ:BZFD) jumped 91.4% to $0.4150 after the company revealed the sale of Complex Networks to NTWRK, a live-streaming video commerce platform. The deal, valued at $108.6 million, will also result in a 16% reduction in BuzzFeed’s workforce.
    • Monopar Therapeutics Inc. (NASDAQ:MNPR) rose 80.7% to $1.03 after the company disclosed promising preclinical data for its MNPR-101 radiopharma program targeting advanced cancers.
    • Root, Inc. (NASDAQ:ROOT) shares gained 40.8% to $12.21 after posting better-than-expected fourth-quarter results.
    • Novavax, Inc. (NASDAQ:NVAX) jumped 34.7% to $5.36. Novavax has reached a settlement related to the 2021 advance purchase agreement for Novavax's prototype Covid-19 vaccine (NVX-COV2373).
    • EZFill Holdings Inc. (NASDAQ:EZFL) rose 34.3% to $1.86. EzFill announced preliminary 2023 revenues of $23 million, up 54% year over year.
    • Mercurity Fintech Holding Inc. (NASDAQ:MFH) jumped 30% to $2.93.
    • Mativ Holdings, Inc. (NYSE:MATV) gained 27.6% to $15.00 following upbeat earnings.
    • Venus Concept Inc. (NASDAQ:VERO) shares climbed 26.9% to $1.6242 after the company received CE Mark from DEKRA Certification B.V. to market Venus Versa Pro in Europe.
    • Outset Medical, Inc. (NASDAQ:OM) gained 26% to $4.0680 following upbeat results.
    • Ocular Therapeutix, Inc. (NASDAQ:OCUL) rose 22.2% to $9.19 after announcing a $325.0 million private placement.
    • Remitly Global, Inc. (NASDAQ:RELY) shares rose 19.5% to $21.13 after the company reported better-than-expected fourth-quarter financial results.
    • B. Riley Financial, Inc. (NASDAQ:RILY) gained 19.3% to $18.13. B. Riley’s board issued a statement regarding internal review.
    • Super Micro Computer, Inc. (NASDAQ:SMCI) jumped 19.2% to $875.07. Supermicro announced a proposed offering of $1.5 billion of convertible senior notes due 2029.
    • Bone Biologics Corporation (NASDAQ:BBLG) gained 18.4% to $3.73.
    • Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) rose 17.5% to $18.00 following strong sales results.
    • ACV Auctions Inc. (NASDAQ:ACVA) gained 16.9% to $16.37 after the company reported better-than-expected fourth-quarter financial results and announced the settlement of its antitrust litigation related to the AutoIMS technology platform.
    • FTI Consulting, Inc. (NYSE:FCN) jumped 15.5% to $219.72 following upbeat results.
    • NVIDIA Corporation (NASDAQ:NVDA) rose 15.4% to $778.61 after the company reported better-than-expected fourth-quarter financial results and issued strong revenue guidance for the first quarter.
    • OUTFRONT Media Inc. (NYSE:OUT) gained 15.4% to $14.35 following upbeat results.
    • Lantheus Holdings, Inc. (NASDAQ:LNTH) rose 14.4% to $64.90 following strong results.
    • Enerplus Corporation (NYSE:ERF) rose 13.7% to $18.67.
    • Indivior PLC (NASDAQ:INDV) gained 13.3% to $19.83 following fourth-quarter results.
    • Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) rose 12.2% to $13.88.
    • Agile Therapeutics, Inc. (NASDAQ:AGRX) gained 11.1% to $1.10. Agile Therapeutics was granted extension by Nasdaq Hearings Panel to regain compliance until March 25, 2024. The company sees FY23 revenue of $20 million to $21 million. Agile Therapeutics announces exercise of warrants for $4.8 million gross proceeds.
    • Synopsys, Inc. (NASDAQ:SNPS) gained 10.7% to $601.93 after the company reported better-than-expected first-quarter adjusted EPS results and issued strong guidance.
    • Q2 Holdings, Inc. (NASDAQ:QTWO) rose 9.5% to $45.82 following strong results.
    • Eastside Distilling, Inc. (NASDAQ:EAST) shares rose 7.6% to $1.0340.
    • DigitalOcean Holdings, Inc. (NYSE:DOCN) gained 6.8% to $38.29 following upbeat results.

    Losers

    • Draganfly Inc. (NASDAQ:DPRO) shares fell 50.3% to $0.1790 after the company announced pricing of $3.6 million underwritten public offering.
    • Greenbrook TMS Inc. (NASDAQ:GBNH) fell 46.6% to $0.2024 after the company announced a $1.2 million registered direct offering of 6 million shares at $0.20 per share purchase price.
    • Synaptogenix, Inc. (NASDAQ:SNPX) shares fell 29.5% to $0.1839 after surging 29% on Wednesday. Synaptogenix received a Notice of Allowance for its U.S. Patent application 17/665,033 titled "Halogenated Esters of Cyclopropanated Unsaturated Fatty Acids for Use in the Treatment of Neurodegenerative Diseases."
    • Rivian Automotive, Inc. (NASDAQ:RIVN) fell 26.8% to $11.25 after the company reported a wider-than-expected loss for its fourth quarter and announced plans to reduce its salaried workforce by around 10% to help further improve costs. The company said it sees production of 57,000 vehicles in 2024.
    • MMTec, Inc. (NASDAQ:MTC) fell 23.2% to $1.0750.
    • Goosehead Insurance, Inc (NASDAQ:GSHD) dipped 21.2% to $68.78 after the company reported worse-than-expected fourth-quarter financial results and issued FY24 revenue guidance below estimates.
    • Bel Fuse Inc. (NASDAQ:BELFA) fell 20.1% to $59.16 after the company reported weak fourth-quarter financial results.
    • Lucid Group, Inc. (NASDAQ:LCID) shares fell 19.1% to $2.9912 after the company reported mixed fourth-quarter financial results and issued guidance.
    • Sunnova Energy International Inc. (NYSE:NOVA) dipped 18.6% to $9.52 after the company reported worse-than-expected fourth-quarter financial results.
    • ATN International, Inc. (NASDAQ:ATNI) declined 18.1% to $29.20 after the company reported fourth-quarter financial results and issued guidance.
    • Pulmonx Corporation (NASDAQ:LUNG) fell 17.6% to $11.94 after the company reported fourth-quarter financial results.
    • MGP Ingredients, Inc. (NASDAQ:MGPI) declined 14.3% to $78.75 after the company reported fourth-quarter financial results.
    • Momentus Inc. (NASDAQ:MNTS) shares fell 13.1% to $0.5995 after declining around 7% on Wednesday.
    • Standard Motor Products, Inc. (NYSE:SMP) dipped 12.7% to $35.01 after the company reported worse-than-expected fourth-quarter financial results and issued guidance.
    • Teekay Corporation (NYSE:TK) gained 12.4% to $7.21 after the company reported a year-over-year decrease in Q4 financial results.
    • TrueCar, Inc. (NASDAQ:TRUE) dipped 11% to $3.4450 following weak sales.
    • Kratos Defense & Security Solutions, Inc. (NASDAQ:KTOS) fell 8% to $18.57. Kratos Defense & Security Solutions announced a proposed public offering of $300 million of common stock.
    • Rogers Corporation (NYSE:ROG) fell 6.8% to $108.29 following weak quarterly results.

     

    Now Read This: Booking Holdings Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

    Get the next $ACVA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACVA
    $AGRX
    $AMLX
    $ATNI

    CompanyDatePrice TargetRatingAnalyst
    Rivian Automotive Inc.
    $RIVN
    3/10/2026$20.00Hold → Buy
    TD Cowen
    Rivian Automotive Inc.
    $RIVN
    3/4/2026$14.00Underperform
    BofA Securities
    Lucid Group Inc.
    $LCID
    3/4/2026$10.00Underperform
    BofA Securities
    Amylyx Pharmaceuticals Inc.
    $AMLX
    3/3/2026$21.00Buy
    Stifel
    Synopsys Inc.
    $SNPS
    2/27/2026$480.00Overweight → Equal-Weight
    Morgan Stanley
    Lantheus Holdings Inc.
    $LNTH
    2/26/2026Mkt Perform → Outperform
    William Blair
    ACV Auctions Inc.
    $ACVA
    2/24/2026Mkt Perform → Outperform
    Barrington Research
    ACV Auctions Inc.
    $ACVA
    2/24/2026$7.00Buy → Neutral
    Citigroup
    More analyst ratings

    $ACVA
    $AGRX
    $AMLX
    $ATNI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    August 30, 2024 - La FDA autoriza la vacuna contra el COVID-19 de Novavax actualizada para brindar una mejor protección contra las variantes que circulan actualmente.

    For Immediate Release: August 30, 2024 English Hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) otorgó una autorización de uso de emergencia (EUA, por sus siglas en inglés) para una versión actualizada de la vacuna contra el COVID-19 de Novavax que ataca más de cerca a las variantes que circulan actualmente para brindar una mejor protección contra las cons

    9/3/24 2:26:49 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    August 30, 2024 - FDA Authorizes Updated Novavax COVID-19 Vaccine to Better Protect Against Currently Circulating Variants

    For Immediate Release: August 30, 2024 Today, the U.S. Food and Drug Administration granted emergency use authorization (EUA) for an updated version of the Novavax COVID-19 vaccine that more closely targets currently circulating variants to provide better protection against serious consequences of COVID-19, including hospitalization and death. The updated vaccine is authorized for use in individuals 12 years of

    8/30/24 2:26:48 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    October 3, 2023 - FDA Authorizes Updated Novavax COVID-19 Vaccine Formulated to Better Protect Against Currently Circulating Variants

    For Immediate Release: October 03, 2023 Today, the U.S. Food and Drug Administration amended the emergency use authorization (EUA) of the Novavax COVID-19 Vaccine, Adjuvanted for use in individuals 12 years of age and older to include the 2023-2024 formula. Individuals 12 years of age and older previously vaccinated with a COVID-19 vaccine (and who have not already been vaccinated with a recently updated mRNA CO

    10/3/23 2:56:27 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $ACVA
    $AGRX
    $AMLX
    $ATNI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Rivian Automotive upgraded by TD Cowen with a new price target

    TD Cowen upgraded Rivian Automotive from Hold to Buy and set a new price target of $20.00

    3/10/26 8:38:01 AM ET
    $RIVN
    Auto Manufacturing
    Industrials

    BofA Securities resumed coverage on Rivian Automotive with a new price target

    BofA Securities resumed coverage of Rivian Automotive with a rating of Underperform and set a new price target of $14.00

    3/4/26 8:39:14 AM ET
    $RIVN
    Auto Manufacturing
    Industrials

    BofA Securities resumed coverage on Lucid Group with a new price target

    BofA Securities resumed coverage of Lucid Group with a rating of Underperform and set a new price target of $10.00

    3/4/26 8:38:27 AM ET
    $LCID
    Auto Manufacturing
    Industrials

    $ACVA
    $AGRX
    $AMLX
    $ATNI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Flatley Jay T bought $25,281 worth of shares (1,830 units at $13.81) and sold $11,775 worth of shares (580 units at $20.30), increasing direct ownership by 0.78% to 162,070 units (SEC Form 4)

    4 - Rivian Automotive, Inc. / DE (0001874178) (Issuer)

    3/5/26 5:10:12 PM ET
    $RIVN
    Auto Manufacturing
    Industrials

    Large owner Hrt Financial Lp bought $15,605 worth of Class A Shares (14,584 units at $1.07) and sold $9,121 worth of Class A Shares (8,368 units at $1.09), increasing direct ownership by 15% to 48,596 units (SEC Form 4)

    4 - La Rosa Holdings Corp. (0001879403) (Issuer)

    3/3/26 2:57:47 PM ET
    $LRHC
    Real Estate
    Finance

    Chief Sales Officer Waterman Michael bought $1,000,036 worth of shares (214,600 units at $4.66), increasing direct ownership by 61% to 569,102 units (SEC Form 4)

    4 - ACV Auctions Inc. (0001637873) (Issuer)

    3/2/26 4:25:53 PM ET
    $ACVA
    Real Estate

    $ACVA
    $AGRX
    $AMLX
    $ATNI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Remus Bourbon Introduces Master Distiller Experimental Series No. 2, Its First-Ever Wheat Whiskey

    The Second Installment of the Series Exemplifies the Indiana-Based Brand's ContinuedCommitment to Innovation and Crafting Bold SpiritsLAWRENCEBURG, Ind., March 10, 2026 /PRNewswire/ -- Today, Remus Bourbon, the award-winning whiskey produced by Ross & Squibb Distillery, known for crafting some of the industry's most recognized whiskeys under the MGP portfolio, announces the release of Remus Master Distiller Experimental Series No. 2, a 113-proof straight wheat whiskey, the first wheat whiskey ever released by the Remus brand. Building on the acclaim of Experimental Series No. 1,

    3/10/26 10:00:00 AM ET
    $MGPI
    Beverages (Production/Distribution)
    Consumer Staples

    IQ.AI by FTI Technology Achieves Measurable Results Globally for World's Largest In-House Legal Teams and Law Firms, Adds IQ.AI Studio

    WASHINGTON, March 10, 2026 (GLOBE NEWSWIRE) -- FTI Consulting, Inc. (NYSE:FCN) announced that adoption for IQ.AI by FTI Technology™ is growing among the world's largest corporate legal departments and law firms, and introduced IQ.AI Studio, a proprietary library of artificial intelligence tasks, models and processes. IQ.AI is patent pending and combines proprietary workflows and expertise with generative AI technology from FTI Technology and its software partners. Launched in 2024, IQ.AI is proven across engagements including antitrust and competition review, post-breach data mining and analysis, cross-border litigations and complex investigations in the Americas, Europe, Asia and Austral

    3/10/26 7:30:00 AM ET
    $FCN
    Professional Services
    Consumer Discretionary

    Synopsys Launches Electronics Digital Twin Platform to Accelerate Physical AI System Development

    Open platform enables seamless integrations with a comprehensive technology ecosystem and cloud‑based deployment to improve engineering collaboration and speed time-to-market for intelligent systemsKey HighlightsOpen platform to create, deploy, manage, and use electronics digital twins, establishing a new integrated and collaborative engineering paradigm across electronics, software, and systemsPre‑integrated Synopsys and ecosystem partner solutions, combined with management and administration capabilities, provide teams ready-to-use, cloud-based environments that reduce development costs, increase product quality, and accelerate innovationInitially focused on high-value automotive use cases

    3/10/26 12:00:00 AM ET
    $SNPS
    Computer Software: Prepackaged Software
    Technology

    $ACVA
    $AGRX
    $AMLX
    $ATNI
    SEC Filings

    View All

    SEC Form S-8 filed by Pulmonx Corporation

    S-8 - Pulmonx Corp (0001127537) (Filer)

    3/10/26 5:19:10 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    SEC Form PRE 14A filed by Lantheus Holdings Inc.

    PRE 14A - Lantheus Holdings, Inc. (0001521036) (Filer)

    3/10/26 5:18:10 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 10-K filed by Pulmonx Corporation

    10-K - Pulmonx Corp (0001127537) (Filer)

    3/10/26 5:03:32 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    $ACVA
    $AGRX
    $AMLX
    $ATNI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by FTI Consulting Inc.

    4 - FTI CONSULTING, INC (0000887936) (Issuer)

    3/10/26 4:56:47 PM ET
    $FCN
    Professional Services
    Consumer Discretionary

    SEC Form 4 filed by FTI Consulting Inc.

    4 - FTI CONSULTING, INC (0000887936) (Issuer)

    3/10/26 4:57:01 PM ET
    $FCN
    Professional Services
    Consumer Discretionary

    SEC Form 4 filed by FTI Consulting Inc.

    4 - FTI CONSULTING, INC (0000887936) (Issuer)

    3/10/26 4:57:13 PM ET
    $FCN
    Professional Services
    Consumer Discretionary

    $ACVA
    $AGRX
    $AMLX
    $ATNI
    Leadership Updates

    Live Leadership Updates

    View All

    PacBio Announces the Appointment of Chris Gibson to the Board of Directors

    MENLO PARK, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading provider of high-quality, long-read sequencing technologies, today announced the appointment of Christopher Gibson, Ph.D., to PacBio's Board of Directors. Dr. Gibson is the co-founder and Chairman of the Board of Directors of Recursion (NASDAQ:RXRX), a clinical-stage biotechnology company that has built one of the industry's most advanced AI-driven drug discovery platforms. Under his leadership, Recursion integrated large-scale biological data generation with machine learning to industrialize the discovery process, building a vertically integrated technology stack spanning automation, high-dimensional b

    3/5/26 8:30:00 AM ET
    $PACB
    $RXRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FTI Consulting Bolsters Mining Sector Expertise in Australia with Addition of Carrie Grimes

    SYDNEY, March 02, 2026 (GLOBE NEWSWIRE) -- FTI Consulting, Inc. (NYSE:FCN) today announced the appointment of Carrie Grimes as a Senior Managing Director in the Business Transformation – Mining practice within the firm's Corporate Finance segment in Australia. Ms. Grimes, who is based in Brisbane, joins with more than 20 years of experience as a trusted advisor working with organisations to define and deliver strategic transformation programs that respond to global trends and drive a competitive edge. Ms. Grimes' experience includes working with global clients in the mining, oil and gas, utilities, and infrastructure industries, with a particular focus on operational improvement, aligning

    3/2/26 4:30:00 PM ET
    $FCN
    Professional Services
    Consumer Discretionary

    Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer

    WILMETTE, Ill., March 02, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR) ("Monopar" or the "Company"), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the appointment of Susan Rodriguez as Chief Commercial and Strategy Officer, effective immediately. In this newly created executive role, Ms. Rodriguez will lead the Company's commercial strategy and infrastructure build-out as Monopar prepares for the planned submission of a New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") in the first half of 2026 for ALXN1840, its late-stage investigational therapy for Wilson d

    3/2/26 8:00:00 AM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACVA
    $AGRX
    $AMLX
    $ATNI
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    What Does the Recent Purchase at Monopar Therapeutics Inc. on Jun 21 Indicate?

    Monopar Therapeutics Inc. has recently seen notable insider activity, with Chief Operating Officer Cittadine Andrew purchasing $25,574 worth of shares on June 21st, 2024. This purchase, comprising 32,508 units at $0.79, increased Cittadine's direct ownership by 21% to 186,132 units as reported in the SEC Form 4. When analyzing this transaction alongside other recent insider activities within the company, interesting patterns and trends start to emerge. Looking back, Cittadine Andrew has been consistently adding to his position in Monopar Therapeutics Inc. over the past few months, showcasing a strong conviction in the company's future prospects. On May 31st, Cittadine Andrew made a substan

    6/22/24 8:00:00 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACVA
    $AGRX
    $AMLX
    $ATNI
    Financials

    Live finance-specific insights

    View All

    Bel Fuse Inc. Announces Acquisition of dataMate, an advanced ethernet and broadband business, from Methode Electronics Inc

    WEST ORANGE, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- Bel Fuse Inc.® (NASDAQ:BELFA) ("Bel" or "the Company"), a leading global manufacturer of products that power, protect and connect electronic circuits, is pleased to announce the acquisition of dataMate®, a leading solutions provider of advanced ethernet and broadband technologies, from Methode Electronics Inc.® Bel acquired dataMate for $16 million, including $1 million of deferred consideration. With annual sales of approximately $18 million and operating margins in line with Bel's corporate averages, the dataMate acquisition is expected to be immediately accretive to Bel's financials. This transaction expands Bel's portfolio and posi

    3/5/26 4:15:00 PM ET
    $BELFA
    $BELFB

    ATN Reports Fourth Quarter and Full Year 2025 Results; Provides 2026 Outlook

    Fourth Quarter and Full Year 2025 Highlights  Fourth quarter high-speed broadband homes passed expanded by 27%Fourth quarter total high-speed broadband subscribers grew by 3%Fourth quarter total international mobile subscribers increased by 3%Fourth quarter revenues increased 2% to $184.2 million; full-year revenues were flat at $728.0 millionFourth quarter operating income increased to $15.7 million; full-year operating income increased to $28.4 millionFourth quarter net loss was $(3.3) million, or $(0.32) per share; full-year net loss was $(14.9) million, or $(1.38) per shareFourth quarter Adjusted EBITDA1 increased 8% to $50.0 million; full-year Adjusted EBITDA1 increased 3% to $190.0 mi

    3/4/26 4:30:00 PM ET
    $ATNI
    Telecommunications Equipment
    Telecommunications

    Pulmonx Reports Fourth Quarter and Full Year 2025 Financial Results

    REDWOOD CITY, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the fourth quarter and full year ended December 31, 2025. Recent Highlights Delivered $90.5 million in worldwide revenue for the full year of 2025, an 8% increase over the prior year and an increase of 7% on a constant currency basisAchieved worldwide revenue of $22.6 million for the fourth quarter of 2025, a 5% decrease over the same period last year and a decrease of 7% on a constant currency basisRealized gross margin of 78% in the fourth quarter of 2025 and 7

    3/4/26 4:06:00 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    $ACVA
    $AGRX
    $AMLX
    $ATNI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Monopar Therapeutics Inc.

    SC 13D/A - Monopar Therapeutics (0001645469) (Subject)

    12/17/24 5:01:42 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Sunnova Energy International Inc.

    SC 13G - Sunnova Energy International Inc. (0001772695) (Subject)

    11/21/24 6:05:56 AM ET
    $NOVA
    Power Generation
    Utilities

    SEC Form SC 13G filed by Indivior PLC

    SC 13G - INDIVIOR PLC (0001625297) (Subject)

    11/15/24 6:03:54 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care